VERTEX PHARMACEUTICALS INC / MA Accounts Receivable 2009-2026 | VRTX
What is accounts receivable?
Accounts receivable represents money owed to the company by customers for goods or services already delivered but not yet paid for.
What is VERTEX PHARMACEUTICALS INC / MA's current accounts receivable?
VERTEX PHARMACEUTICALS INC / MA (VRTX) annual accounts receivable for 2025 was $2.05B, a 27.55% increase from 2024. VERTEX PHARMACEUTICALS INC / MA accounts receivable for the quarter ending March 31, 2026 was $2.00B.
What was VERTEX PHARMACEUTICALS INC / MA's accounts receivable in 2024?
VERTEX PHARMACEUTICALS INC / MA annual accounts receivable for 2024 was $1.61B, a 2.94% increase from 2023.
What was VERTEX PHARMACEUTICALS INC / MA's accounts receivable in 2023?
VERTEX PHARMACEUTICALS INC / MA annual accounts receivable for 2023 was $1.56B, a 8.40% increase from 2022.
What is VERTEX PHARMACEUTICALS INC / MA's 5-year accounts receivable CAGR?
VERTEX PHARMACEUTICALS INC / MA accounts receivable grew at a compound annual growth rate (CAGR) of 18.32% from FY2020 to FY2025, going from $885.4M to $2.05B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $2.05B | +27.6% | 10-K |
| FY2024 | $1.61B | +2.9% | 10-K |
| FY2023 | $1.56B | +8.4% | 10-K |
| FY2022 | $1.44B | +26.9% | 10-K |
| FY2021 | $1.14B | +28.4% | 10-K |
| FY2020 | $885.4M | +39.8% | 10-K |
| FY2019 | $633.5M | +54.6% | 10-K |
| FY2018 | $409.7M | +45.6% | 10-K |
| FY2017 | $281.3M | +40.4% | 10-K |
| FY2016 | $200.4M | +15.3% | 10-K |
| FY2015 | $173.8M | +128.8% | 10-K |
| FY2014 | $76.0M | -11.2% | 10-K |
| FY2013 | $85.5M | -40.3% | 10-K |
| FY2012 | $143.3M | -21.8% | 10-K |
| FY2011 | $183.1M | +1361.7% | 10-K |
| FY2010 | $12.5M | +30.5% | 10-K |
| FY2009 | $9.6M | - | 10-K |